Logo image of TKAI

Tokai Pharmaceuticals Inc. (TKAI) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:TKAI -

0.61
-0.03 (-4.69%)
Last: 5/10/2017, 8:13:03 PM
0.564
-0.05 (-7.54%)
After Hours: 5/3/2017, 8:20:55 PM

TKAI Key Statistics, Chart & Performance

Key Statistics
Market Cap13.81M
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares22.64M
FloatN/A
52 Week High7.65
52 Week Low0.52
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-2.01
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
TKAI short term performance overview.The bars show the price performance of TKAI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

TKAI long term performance overview.The bars show the price performance of TKAI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TKAI is 0.61 null. In the past month the price decreased by -7.58%. In the past year, price decreased by -91.16%.

Tokai Pharmaceuticals Inc. / TKAI Daily stock chart

TKAI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TKAI Financial Highlights

Over the last trailing twelve months TKAI reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS increased by 59.1% compared to the year before.


Industry RankSector Rank
PM (TTM) 100.27%
ROA -87.37%
ROE -101.88%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.18%
Sales Q2Q%N/A
EPS 1Y (TTM)59.1%
Revenue 1Y (TTM)N/A

TKAI Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y-3.48%
Revenue Next YearN/A

TKAI Ownership

Ownership
Inst Owners10.97%
Ins Owners57.61%
Short Float %N/A
Short RatioN/A

About TKAI

Company Profile

Tokai Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. Tokai Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Company Info

Tokai Pharmaceuticals Inc.

255 STATE STREET 6TH FLOOR

BOSTON MA 02109

CEO: Jodie P. Morrison

Phone: 617-225-4305

Tokai Pharmaceuticals Inc. / TKAI FAQ

What does Tokai Pharmaceuticals Inc. do?

Tokai Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. Tokai Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.


Can you provide the latest stock price for Tokai Pharmaceuticals Inc.?

The current stock price of TKAI is 0.61 null. The price decreased by -4.69% in the last trading session.


Does Tokai Pharmaceuticals Inc. pay dividends?

TKAI does not pay a dividend.


What is the ChartMill technical and fundamental rating of TKAI stock?

TKAI has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.


Is Tokai Pharmaceuticals Inc. (TKAI) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TKAI.